Value
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.2 |
| P/S | 8.9 |
| EV/EBITDA | 2.4 |
| Fwd P/E | 6.1 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 21.2x
- ▸PEG: 0.46
- ▸Attractively valued
MDLN · Why this verdict
Why Medline (MDLN) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Medline enters the analysis with 23% upside to the analyst price target and a 3.3-to-1 favorable risk/reward — supported by consecutive earnings beats and a near-perfect Piotroski financial-health score — but heavy reliance on three group-purchasing organizations for approximately 69% of revenues remains the central concentration risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Approximately 69% of revenues flow through three group purchasing organizations; renegotiation, pricing pressure, or loss of a single GPO relationship could materially impair the revenue base with limited ability to replace the volume quickly. Bear case | GPO-channel concentration declines toward 60% or below over the next two years as direct and alternate channel revenues grow faster than the GPO base. | →Stable |
| CounterGPO relationships in medical supplies tend to be long-term and sticky, with meaningful switching costs that protect incumbents; the concentration reflects the structure of the market rather than unique fragility in this company's commercial model. | ||
At current prices there is approximately 23% upside to the consensus analyst target, with a risk/reward ratio of roughly 3.3-to-1 in the investor's favor — a setup that comfortably clears the asymmetry threshold needed for a meaningful position. Price targets | The stock closes at least half the gap to the $45.90 analyst target within the next 12 months as earnings momentum is recognized by the broader market. | →Stable |
| CounterAnalyst price targets for recently public medical-supplies companies can carry wide uncertainty bands; a 23% implied upside may be based on assumptions that have not yet been stress-tested across a full market cycle. | ||
Both reported quarters beat consensus — the most recent by 12% and the prior one by approximately 60% — signaling that management is establishing an early pattern of consistently delivering above expectations. Earnings | EPS beats consensus in each of the next two quarters, extending the streak to four consecutive beats. | →Stable |
| CounterWith only two quarters of public reporting history there is insufficient data to distinguish a durable beat cadence from a launch-quarter honeymoon effect; a single miss would collapse the entire track record. | ||
A Piotroski F-Score of 8 out of 9 signals broad financial soundness across profitability, leverage, and efficiency dimensions, reducing the risk that balance-sheet deterioration compounds the other risks in the near term. Quality breakdown | The Piotroski score remains at 7 or above over the next four quarters, confirming financial discipline as the company scales. | →Stable |
| CounterA high Piotroski score captures financial health at a point in time; for a company in a growth investment phase, profitability and leverage metrics can erode quickly if the company accelerates spending or takes on acquisition-related debt. | ||
Approximately 69% of revenues flow through three group purchasing organizations; renegotiation, pricing pressure, or loss of a single GPO relationship could materially impair the revenue base with limited ability to replace the volume quickly.
→StableBear case
- Expectation
- GPO-channel concentration declines toward 60% or below over the next two years as direct and alternate channel revenues grow faster than the GPO base.
CounterGPO relationships in medical supplies tend to be long-term and sticky, with meaningful switching costs that protect incumbents; the concentration reflects the structure of the market rather than unique fragility in this company's commercial model.
At current prices there is approximately 23% upside to the consensus analyst target, with a risk/reward ratio of roughly 3.3-to-1 in the investor's favor — a setup that comfortably clears the asymmetry threshold needed for a meaningful position.
→StablePrice targets
- Expectation
- The stock closes at least half the gap to the $45.90 analyst target within the next 12 months as earnings momentum is recognized by the broader market.
CounterAnalyst price targets for recently public medical-supplies companies can carry wide uncertainty bands; a 23% implied upside may be based on assumptions that have not yet been stress-tested across a full market cycle.
Both reported quarters beat consensus — the most recent by 12% and the prior one by approximately 60% — signaling that management is establishing an early pattern of consistently delivering above expectations.
→StableEarnings
- Expectation
- EPS beats consensus in each of the next two quarters, extending the streak to four consecutive beats.
CounterWith only two quarters of public reporting history there is insufficient data to distinguish a durable beat cadence from a launch-quarter honeymoon effect; a single miss would collapse the entire track record.
A Piotroski F-Score of 8 out of 9 signals broad financial soundness across profitability, leverage, and efficiency dimensions, reducing the risk that balance-sheet deterioration compounds the other risks in the near term.
→StableQuality breakdown
- Expectation
- The Piotroski score remains at 7 or above over the next four quarters, confirming financial discipline as the company scales.
CounterA high Piotroski score captures financial health at a point in time; for a company in a growth investment phase, profitability and leverage metrics can erode quickly if the company accelerates spending or takes on acquisition-related debt.
Per-dimension breakdown
Quality
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.0 |
| Gross margin | 1.2 |
| Op margin | 2.2 |
| Net margin | 1.7 |
| Current ratio | 8.6 |
| Moat | 5.6 |
| Piotroski F | 8.9 |
- ▸Strong Piotroski F-Score: 8/9
Growth
7.6/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.2 |
| EPS growth | 10.0 |
Momentum
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 5.5 |
| Volume | 0.3 |
- ▸Volume distribution (falling OBV)
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 9.3 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 42%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.5 |
| holder change | 5.4 |
- ▸Heavy insider selling — $3,598,914,948 (5.722% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.3 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.3 |
| support resistance | 3.5 |
| 52w position | 4.2 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 8.9 |
| volatility | 1.5 |
| put call | 0.0 |
| implied vol | 4.7 |
| debt equity | 7.1 |
- ▸Elevated put/call: 4.50
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (7)
- ASYMMETRY:3.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.3<4.5
Warning (0)
none
Reward-to-Risk
3.08
Upside
+27.7%
Downside
9.0%
Sizing output
AVOID
SetupRANGE_BOUND — RSI 58 mid-range, Bollinger mid-band
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: ASYMMETRY:3.1>=1.5. Top dim: Growth at 7.6; weakest: Insider at 3.3. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 7.6, Catalyst at 7.5, and Sentiment at 7.4; the weakest are Insider at 3.3, Peer rank at 3.8, and Technical at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 3.08 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1At current prices there is approximately 23% upside to the consensus analyst target, with a risk/reward ratio of roughly 3.3-to-1 in the investor's favor — a setup that comfortably clears the asymmetry threshold needed for a meaningful position.
Trip ifUpside to the analyst consensus price target falls below 10% as the stock price appreciates faster than target revisions.
- P2Both reported quarters beat consensus — the most recent by 12% and the prior one by approximately 60% — signaling that management is establishing an early pattern of consistently delivering above expectations.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, reversing the early beat pattern.
- P3Approximately 69% of revenues flow through three group purchasing organizations; renegotiation, pricing pressure, or loss of a single GPO relationship could materially impair the revenue base with limited ability to replace the volume quickly.
Trip ifGPO-channel revenue share falls below 55% of total revenues, demonstrating meaningful customer diversification has occurred.
- P4A Piotroski F-Score of 8 out of 9 signals broad financial soundness across profitability, leverage, and efficiency dimensions, reducing the risk that balance-sheet deterioration compounds the other risks in the near term.
Trip ifPiotroski F-Score deteriorates to 5 or below for 2 consecutive quarters, signaling broad financial weakening.